Alteration of TAGLN2 expression has been noted in different types of cancer at both the transcriptional and translational levels, and cancer cell proliferation, invasion, and metastasis might be inhibited by suppressing TAGLN2. Tumorigenesis and tumor development may be correlated with the deregulation of TAGLN2. Tumor size, clinical stage, histological neural invasion, and lymph node metastasis are closely associated with TAGLN2 in bladder cancer [37], colorectal cancer [38, 39], esophageal cancer [24], and gastric cancer [40]. Here, TAGLN2 is linked to metastatic malignant neoplasm in the lymph nodes.